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ABSTRACT  
BACKGROUND: When health state utility values for comorbid health conditions are not 
available, analysts frequently use data from cohorts with single health conditions to estimate 
proxy scores.  The methods used can produce very different results and there is currently no 
consensus on which is the most appropriate approach. 
OBJECTIVE: The objective of the current study was to assess the accuracy of five different 
methods that have been used to estimated HSUVs for comorbid health conditions. 
METHOD: Data collected during five Welsh Health Surveys (WHS) were subgrouped by 
health status.  Mean SF-6D scores from cohorts with a particular health condition were used 
to estimate mean SF-6D scores for cohorts with two comorbid health conditions using:the 
additive, multiplicative, and minimum methods, and the adjusted decrement estimator.  A 
linear model was obtained by regressing mean HSUV from subgroups with single health 
conditions onto mean HSUVs from subgroups with combined health conditions. 
RESULTS: The pooled WHS data provided 64,437 cases with SF-6D scores. When 
subgrouped by self reported health condition(s), 32 groups (n>30) were identified with 
comorbid health conditions.  The mean SF-6D for these subgroups ranged from 0.4648 to 
0.6068.  The linear model produced the most accurate HSUVs for the combined health 
conditions with 88% of values accurate to within the minimum important difference for the 
SF-6D.  The additive method underestimated the actual SF-6D scores and produced some 
substantial errors in the estimated values.  The minimum method overestimated all mean SF-
6D scores but was more accurate when estimating higher values.  The multiplicative and ADE 
methods both underestimated the majority of the actual SF-6D scores.  However, both 
methods both performed better when estimating SF-6D scores smaller than 0.50 with 43% 
and 86% of estimated HSUVs accurate to within the MID for the multiplicative and ADE 
respectively. 
This study makes an important contribution to the existing evidence as it is the first to 
compare five different methods on SF-6D data. Although the range in actual HSUVs was 
relatively small, the data covered the lower end of the index while the majority of previous 
research has involved actual HSUVs covering the upper end of possible ranges.  While the 
linear model gave the most accurate results in our data, additional research is required to 
develop and validate the model. 
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BACKGROUND 
Policy decision makers such as the National Institute for Health and Clinical Excellence 
(NICE) in the UK recommend that the results of economic evaluations in healthcare are 
presented in terms of quality adjusted life years (QALY).[1]  The QALY quantifies both 
health related quality of life and life expectancy in a single metric and allows comparison 
across disparate diseases and interventions.[2]  The health state utility values (HSUVs) used 
to weight the QALYs are obtained from preference-based measures of health such as the EQ-
5D, and the SF-6D.[3,4] 
 
While there is a large evidence base for HSUVs associated with single health conditions, due 
to the large number of possible combinations of health conditions, studies reporting HSUVs 
for comorbid health conditions are limited.  When these data are not available HSUVs for 
comorbid health conditions are estimated using the HSUVs obtained from people with single 
conditions.  For example, the mean HSUV for a comorbid health condition defined as both 
condition A and condition B would be estimated using the mean HSUVs obtained from 
cohorts with condition A (but not condition B) and the mean HSUV from cohorts with 
condition B (but not condition A).  The three most frequently used techniques are the 
additive, multiplicative and minimum methods.  The additive and multiplicative methods 
assume a constant absolute or constant proportional decrement respectively while the 
minimum method attributes no additional health decrement, taking the smallest HSUV from 
the single health conditions involved. 
 
The evidence base describing empirical research in this area is limited and there is currently 
no consensus on the most appropriate approach.  The multiplicative method gave a good fit on 
HUI3 data from the Canadian Community Health Survey;[5] and was more accurate than the 
additive method on EQ-5D data from the Medical Expenditure Panel Survey (MEPS).[6]  The 
minimum method performed better than both the additive and the multiplicative methods on 
EQ-5D data from the MEPS.[7]  More recently, a variation of the minimum method, the 
adjusted decrement estimator (ADE) has been proposed and was shown to outperform the 
three other methods on EQ-5D data from MEPS.[8] 
 
The methods can produce very different HSUVs and it has been shown that these differences 
are great enough to potentially influence a policy decision based on a cost per QALY 
threshold.[9]  This undermines the rational for consistent reimbursement recommendations 
and optimal resource allocation.  The objective of the current study was to assess the accuracy 
of all four methods using SF-6D data collected in the Welsh Health Surveys.  We compare 
these results with values predicted using a parametric model which maps from mean HSUVs 
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obtained from cohorts with single health conditions onto HSUVs for cohorts with comorbid 
health conditions. 
 
 
 
METHODS 
The Welsh Health Survey (WHS) is an annual survey which draws from a random sample of 
the population living in private households in Wales.[10-14]  Responses collected during the 
surveys conducted in the years 2003, 2004, 2005, 2007 and 2008 were pooled for use in the 
current study.  HSUVs were obtained using the SF-6D (v2) preference-based measure which 
is derived from responses to the SF-36 generic health questionnaire.[15]  The SF-6D is a six-
dimensional health state classification system assessing physical functioning, role-limitations, 
social functioning, pain, mental health and vitality.  The classification system generates a total 
of 18,000 possible health states.  Weights for the SF-6D preference-measure used in the 
current study were obtained from a random sample of the UK general population using 
anchors of zero and one to represent death and perfect health respectively.[3]  The SF-6D is 
scored on a continuous index whereby 0.296 represents the maximum impaired level on all 
six dimensions and 1 represents the least impaired level. 
 
In addition to questions on health related quality of life, respondents were asked to identify if 
limiting long term health conditions and the coded data details information on 39 individually 
categorised and 14 grouped limiting long term health conditions (see online Appendix A).  
All analyses are weighted using the individual level self-administered questionnaire weights 
which adjusts for non response. 
 
The “actual” mean SF-6D scores were calculated for subgroups (n ≥ 30) of respondents with 
comorbid pairs of health conditions (condition A and condition B), and for subgroups with 
condition A (and not condition B) or condition B (and not condition A).  The latter were then 
used to estimate mean SF-6D scores for the cohorts with comorbid health conditions using the 
methods described below.  The relationship between the SF-6D scores from cohorts with 
single health conditions and the actual SF-6D scores was also explored using ordinary least 
square regression (OLS).  The OLS model incorporates the additive and minimum method 
with a multiplicative interaction term as described in the next section. 
 
Methods used to estimate HSUVs 
For the two health conditions, condition A and condition B, the following combinations are 
possible: condition A and condition B; neither condition A or condition B; condition A but 
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not condition B; condition B but not condition A.  The HSUVs associated with these 
alternatives are defined to be UA,B, UnA,nB, UA, and UB respectively. 
 
The additive method assumes a constant absolute detriment relative to the baseline.  When  
assuming a baseline of full health the additive method is written as: 
    BA
add
BA UUU  111,      (1) 
Using an adjusted baseline (see next section) the additive method is written as: 
    BnbAnAnBnA
add
BA UUUUUU  ,,     (2) 
 
The multiplicative method assumes a constant proportional detriment relative to the baseline.  
When assuming a baseline of full health, the multiplicative method is written as: 
BA
mult
BA UUU ,       (3) 
When using an adjusted baseline, the multiplicative method is written as:  
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The minimum method assumes the impact on HRQoL for a comorbid health condition is 
equivalent to the most severe of the single health conditions. I.e. there is no additional 
decrement associated with a second health condition.  When assuming a baseline of full 
health, the minimum method is written as: 
     BABA UUU ,minˆ
min
,      (5) 
When using an adjusted baseline, the minimum method is written as:  
 BAnBnABA UUUU ,,min ,min,       (6) 
 
The adjusted decrement estimator (ADE), proposed by Hu, assumes the HSUV for the 
comorbid health condition is bound by the minimum HSUV of the two HSUVs for the single 
health conditions and is written as:[8] 
       BABABA
ADE
BA UUUUUUU  11,min,min,   (7) 
 
In addition to the methods described above, a simple linear model has been proposed.[16]  
Based on decision theory, multi-attribute utility functions,[17,18] and a prospect theory[19] 
the model incorporates terms that represent the additive, multiplicative and minimum 
methods.[16]  The model is defined by: 
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whereby the beta coefficients are obtained using ordinary least square regressions and   
represents the residual.  We use the following adaptation which incorporates an adjusted 
baseline: 
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When using a baseline of full health it is assumed that if a particular health condition is 
alleviated, the HSUV for the health condition will revert to 1 on a preference based utility 
index.  However, this assumption ignores the natural decline in health due to age and 
additional comorbidities and overestimates the decrement on health related quality of life 
associated with health conditions.[20]  Consequently this may not be the most appropriate 
technique when estimating HSUVs for comorbid health conditions.  Several alternatives have 
been suggested and these include: “purifying” data by dividing all HSUVs by the mean 
HSUV obtained from individuals with none of the health conditions,[5] or using HSUVs 
associated with not having specific health conditions.[6]  We used age adjusted baseline 
HSUVs obtained from respondents who do not have any of the health conditions identified in 
the WHS. 
 
The methods used to estimate HSUVs for the combined health conditions were assessed in 
terms of errors (actual minus estimated) in the estimated HSUVs.  In addition to the statistics 
generally reported (mean absolute errors (MAE), mean squared errors (MSE), root mean 
squared error (RMSE)), the proportion of errors within the minimum important difference 
(MID) for the SF-6D (MID = 0.041)[21] were calculated and the magnitude of errors across 
the actual SF-6D scores were examined using scatter plots 
 
 
 
RESULTS 
The pooled data included 64,437 cases with SF-6D scores.  The mean SF-6D for the full 
sample irrespective of health status was 0.7613 (range 0.301 to 1).  The mean SF-6D for 
respondents (16414/64437) who reported having at least one limiting long term health 
condition was 0.6055 (se 0.0011) compared with 0.8104 (se 0.0006) for respondents who 
reported no limiting long term health condition.  There were just 2,021 respondents who 
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reported two or more limiting long term illnesses and 32 subgroups (n≥30) with two 
concurrent conditions (see Appendix for details).  The mean SF-6D scores (Figure 1) for these 
subgroups ranged from 0.4648 (se 0.0086) for respondents (n=140) who reported both a 
mental disorder and a musculoskeletal condition to 0.6068 (se 0.0269) for respondents (n=33) 
who reported both arthritis/ rheumatism/fibrositis and an unclassifiable complaint.  As can be 
seen in Figure 1, the SF-6D scores are clustered around the mean (0.5301) with just 4/32 
groups scoring less than 0.50 or greater than 0.60.  When comparing mean SF-6D scores for 
subgroups, all scores from the groups with comorbid health conditions were smaller than 
those from the subgroups with the corresponding single health conditions. 
 
INSERT FIGURE 1: Distribution of mean SF-6D scores for subgroups (n=32) with two 
comorbid health conditions 
 
The linear model estimated using ordinary least squares is provided in Table 1.  The 
coefficients for all three independent variables are negative as would be expected as they are 
the decrements associated with the health conditions.  When comparing the magnitude of the 
coefficients, the coefficient for the condition with the maximum decrement is larger than the 
coefficient for the condition with the minimum decrement as might be expected.  The weight 
associated with the interaction term (p = 0.661) is similar to that for the health condition with 
the minimum disutility. 
 
 
INSERT TABLE 1: Results from the OLS combination model 
 
 
A summary of the results obtained using the five alternative techniques is provided in Table 2.  
Overall, the HSUVs obtained using the linear model are the most accurate producing the 
smallest MAE (0.0191) and the smallest RMSE (0.0254) in the predicted mean SF-6D values.  
Although the average of the predicted mean SF-6D scores equals the actual value of 0.5301, 
the range is somewhat truncated (predicted range: 0.4935 to 0.5549, actual range: 0.4368 to 
0.6068).  However, all predicted HSUVs are within the MID for the SF-6D and 75% have 
errors smaller than |0.025|. 
 
Of the four nonparametric methods, the ADE outperforms the other three having the smallest 
MAE (0.0419) and smallest RMSE (0.0471).  When examining accuracy in predicting the 
individual mean SF-6D scores, the ADE does not compare favourably with the linear model 
and only 47% (25%) of estimated HSUVs are accurate to within the |MID| (|0.025|).  The 
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additive, multiplicative and minimum methods perform less well with just 3%, 6%, and 13% 
of estimated HSUVs within the |MID| respectively. 
 
INSERT TABLE 2: Comparing the predictive abilities of the four methods 
 
Figure 2 shows the actual and estimated mean SF-6D scores.  It is clear that the minimum 
method overestimates the actual SF-6D scores and the errors increase as the actual SF-6D 
score decreases.  The additive, multiplicative and ADE methods underestimate the majority of 
the actual SF-6D scores.  While the linear model produces the most accurate scores there is a 
tendency for the errors to be larger at the extremes of the range of actual scores. 
 
INSERT FIGURE 2: Plot of actual and estimated SF-6D scores 
 
When sub-grouped by actual SF-6D score (Table 3) it can be seen that the value of the SF-6D 
score being estimated can influence the accuracy of the methods.  For example, while the 
minimum method was the least accurate in terms of mean errors overall, it performs better 
than all the other nonparametric methods when estimating actual SF-6D scores greater that 
0.55 and 71% of these estimated values are accurate to within the MID.  Similarly, when 
estimated SF-6D smaller than 0.50, the ADE produces 86% of HSUVs accurate to within the 
MID compared with 57% of values predicted using the linear model.  The additive method 
does not perform well across the full range of actual SF-6D scores while the multiplicative 
method performs better when estimating SF-6D scores smaller than 0.50. 
 
 
 
DISCUSSION 
The objective of the current study was to add to the existing evidence base by comparing the 
accuracy of methods frequently used to estimate HSUVs for comorbid health conditions.  
Using SF-6D data obtained from respondents taking part in Welsh Health Surveys, we found 
that the linear model obtained using OLS regression out-performed the non parametric 
methods.  Overall 88% of HSUVs predicted using the linear model were within the MID of 
the SF-6D.  The additive method underestimated the actual SF-6D scores and produced some 
substantial errors with none of the estimated HSUVs within the MID for the SF-6D.  
Although the minimum method overestimated the actual HSUVs it performed better when 
estimating SF-6D scores greater than 0.55 with errors in estimated values increasing as actual 
SF-6D scores decreased.  The multiplicative and ADE methods both underestimated the 
majority of the actual SF-6D scores.  However, when looking at subgroups of actual SF-6D 
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scores, both methods both performed better when estimating SF-6D scores smaller than 0.50 
with 43% and 86% of estimated HSUVs accurate to within the MID for the multiplicative and 
ADE respectively. 
 
Our findings are similar to those reported in a recent publication using EQ-5D data obtained 
from the MEPS.[8]  The range in actual HSUVs for the comorbid health conditions ranged 
from 0.62 to 0.88 and the authors reported the ADE model outperformed the additive, 
minimum and multiplicative methods when assessed by MEs and RMSE in estimated values.  
Charts of the estimated and actual EQ-5D scores showed the additive and multiplicative 
methods underestimated the actual EQ-5D scores and the magnitude of errors increased as the 
actual EQ-5D score increased for both methods.  As in our data, the minimum method 
performed better for higher HSUVs with the magnitude of errors increasing as the actual 
HSUV decreased.  While the ADE performed better than the other methods overall, the 
magnitude of errors in estimated values grew substantially as the actual EQ-5D score 
decreased. 
 
There are three limitations relating to the data used in the current study.  First, the range in 
actual mean SF-6D scores (0.4648 to 0.6068) for the comorbid health conditions covered only 
24% of the possible range (0.29 to 1) and all values were in the bottom half of the SF-6D 
index (i.e. below 0.65).  Actual mean HSUVs for comorbid health conditions reported in other 
studies tend to be in the upper range of the preference based indices.  For example, Hu and Fu 
used data from MEPS and their actual EQ-5D scores ranged from 0.62 to 0.88 which equates 
to 24% of the possible range (-0.1 to 1) for the US EQ-5D index.[7,8,22] Janssen used a 
similar dataset and reported actual mean EQ-5D scores for comorbid health conditions 
ranging from (0.734 to 0.819).[6]  The widest range (-0.01 to 1) of actual mean HSUVs for 
comorbid conditions was reported in a dataset of HUI3 scores obtained from the Canadian 
Community Health Survey (2001, 2003).  However, the majority (184/278) of scores were 
greater than 0.80.  One possible explanation for the differences in the ranges for the actual 
HSUVs is that the respondents in our dataset were asked to identify limiting long standing 
illnesses, while the respondents in the surveys for the other studies were asked to identify 
chronic health conditions.  The consequence of this is that the respondents in the WHS may 
not have reported health conditions they did not perceive to affect their HRQoL.  As the 
accuracy in the estimating methods has been show to vary depending on the range of the 
scores estimated in both this study and Hu’s it is possible that different conclusions would be 
drawn if the methods were tested in datasets that covered the full ranges of the indices. 
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Second, we were only able to identify 32 subgroups with comorbid health conditions and the 
number of cases in some of the subgroups was relatively small (n= 30 to 346).  As a 
consequence we did not estimate HSUVs for comorbid health conditions consisting of greater 
than two health conditions.  While Flanagan et al. assessed the accuracy of the multiplicative 
method in estimating HSUVs for comorbid health conditions consisting of more than two 
health conditions, as far as we are aware, this is the only research in this area and no-one has 
compared results for multiple comorbid health conditions using alternative methods to 
date.[5] 
 
Third, although we obtained a linear model to predict SF-6D scores for the comorbid health 
conditions, the number of cases used in the regression was small (n=32) and none of the 
coefficients in the model were statistically significant.  As the model tends to over predict the 
lower SF-6D scores and under predict the higher SF-6D scores it is possible that a different 
model specification would produce more accurate results and additional research exploring 
alternatives is warranted. 
 
CONCLUSION 
Despite the limitations in the data, this study makes an important contribution to the evidence 
base.  It is the first study to compare the five different techniques on SF-6D data and although 
the range of estimated scores was relatively small, they covered the lower end of the 
preference based index whilst the majority of other research in this area has involved actual 
HSUVs at the top end of the preference measures.  While the linear model gave the most 
accurate results in our sample, additional research is required to develop and validate the 
model. 
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Table 1 : Results from the OLS combination model 
Independent variable Coefficient Robust Std. Err. P>|t| 
Maximum decrement  -1.049809 0.6162 0.099 
Minimum decrement -0.4797101 0.89592 0.597 
Interaction of utilities -0.4986031 1.12376 0.661 
Constant   1.0606200 0.77913 0.184 
 
R Sq 0.3472 
 
Maximum decrement     BnbAnA UUUU  ,max  
Minimum decrement     BnbAnA UUUU  ,min  
Interaction of utilities 







nb
B
nA
A
nBnA
U
U
U
U
U ,  
 
 
 
 14 
Table 2: Comparing the predictive abilities of the four methods  
 Actual Estimated  
  Additive Multiplicative Minimum ADE 
(Hu) 
Linear 
model 
       
Mean SF-6D  0.5301 0.4092 0.4556 0.5848 0.4918 0.5301 
Min SF-6D  0.4368 0.3453 0.4115 0.5620 0.4656 0.4935 
Max SF-6D  0.6068 0.4794 0.5077 0.6053 0.5169 0.5549 
Range: 0.1700 0.1341 0.0962 0.0433 0.0513 0.0614 
Mean error 0.1209 0.0745 -0.0546 0.0383 0.0000 
Maximum absolute error 0.1924 0.1496 0.1316 0.1196 0.0669 
       
MAE  0.1209 0.0747 0.0563 0.0419 0.0191 
MSE  0.0157 0.0064 0.0038 0.0022 0.0006 
RMSE  0.1252 0.0799 0.0613 0.0471 0.0254 
Proportion within |0.01| 0% 3% 0% 0% 31% 
Proportion within |0.025| 0% 6% 6% 25% 75% 
       
Proportion within MID |0.041| 3% 6% 13% 47% 88% 
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Table 3 : Errors in estimated HSUVs subgrouped by actual SF-6D score 
 Actual SF-6D score n Additive Multiplicative Minimum ADE (Hu) 
Linear 
model 
Mean error 
SF-6D > 0.55 7 0.1399 0.0943 -0.0260 0.0636 0.0256 
0.55 ≤ SF-6D < 0.50 18 0.1271 0.0762 -0.0528 0.0403 -0.0003 
SF-6D ≥ 0.50 7 0.1105 0.0463 -0.0880 0.0080 -0.0249 
Mean absolute error 
SF-6D > 0.55 7 0.1399 0.0943 0.0334 0.0636 0.0256 
0.55 ≤ SF-6D < 0.50 18 0.1271 0.0762 0.0528 0.0403 0.0120 
SF-6D ≥ 0.50 7 0.1105 0.0463 0.0880 0.0243 0.0308 
 Root mean squared error  
SF-6D > 0.55 7 0.1430 0.0978 0.0342 0.0683 0.0324 
0.55 ≤ SF-6D < 0.50 18 0.1302 0.0788 0.0545 0.0430 0.0152 
SF-6D ≥ 0.50 7 0.1172 0.0553 0.0916 0.0270 0.0360 
Accurate to within the |MID| 
SF-6D > 0.55 7 0% 0% 71% 0% 86% 
0.55 ≤ SF-6D < 0.50 18 0% 6% 17% 50% 100% 
SF-6D ≥ 0.50 7 14% 43% 0% 86% 57% 
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Figure 1: Distribution of mean SF-6D scores for subgroups (n=32) with two comorbid health 
conditions 
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Figure 2: Actual and estimated mean SF-6D scores  
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APPENDIX A: 
TableA1 description of comorbid conditions and mean SF-6D scores 
  N Mean SF-6D score 
   Condition 
Age adjusted baseline  
(from respondents with none of 
health conditions 
Condition A Condition B N 
Condition A&B 
(Actual) 
Condition A 
(not Condition B) 
Condition B 
(not Condition A) Condition A Condition B 
endocrine and metabolic diseases heart and circulatory  85 0.5553 0.6372 0.5993 0.7933 0.7808 
endocrine and metabolic diseases musculoskeletal 103 0.5523 0.6393 0.5967 0.7924 0.7922 
mental disorders nervous system  34 0.5020 0.5671 0.5862 0.8127 0.8033 
mental disorders heart and circulatory  45 0.5161 0.5672 0.5994 0.8132 0.7803 
mental disorders musculoskeletal 140 0.4648 0.5788 0.5985 0.8133 0.7919 
nervous system musculoskeletal 139 0.5340 0.5905 0.5972 0.8037 0.7920 
eye complaints musculoskeletal  33 0.5052 0.6691 0.5965 0.7801 0.7923 
ear complaints musculoskeletal  40 0.5405 0.6662 0.5964 0.7936 0.7922 
heart and circulatory respiratory system  85 0.5316 0.6002 0.6167 0.7808 0.7911 
heart and circulatory musculoskeletal 277 0.5377 0.6058 0.5981 0.7812 0.7927 
respiratory system musculoskeletal 175 0.5378 0.6222 0.5974 0.7903 0.7921 
digestive system musculoskeletal  82 0.5475 0.6250 0.5966 0.7978 0.7922 
genito-urinary system musculoskeletal  30 0.5232 0.6299 0.5964 0.7961 0.7921 
musculoskeletal skin complaints  38 0.5615 0.5963 0.6568 0.7921 0.8064 
diabetes. incl. hyperglycemia arthritis/rheumatism/fibrositis 34 0.5434 0.6351 0.5815 0.7895 0.7855 
mental illness/anxiety/depression/nerves arthritis/rheumatism/fibrositis 104 0.4368 0.5684 0.5837 0.8129 0.7851 
mental illness/anxiety/depression/nerves back problems/slipped disc/spine/neck 126 0.4778 0.5641 0.6049 0.8126 0.8043 
mental illness/anxiety/depression/nerves other problems of bones/joints/muscles 36 0.5093 0.5620 0.6099 0.8124 0.7920 
other problems of nervous system arthritis/rheumatism/fibrositis 49 0.5218 0.5700 0.5820 0.8012 0.7854 
other problems of nervous system back problems/slipped disc/spine/neck 30 0.5146 0.5693 0.6037 0.8005 0.8044 
other problems of nervous system other problems of bones/joints/muscles 158 0.5480 0.5676 0.6093 0.8008 0.7921 
heart attack/angina other heart problems 36 0.5437 0.6184 0.5951 0.7783 0.7793 
heart attack/angina arthritis/rheumatism/fibrositis 168 0.5405 0.6216 0.5816 0.7784 0.7857 
hypertension/high blood pressure/blood p arthritis/rheumatism/fibrositis 31 0.5576 0.6301 0.5814 0.7881 0.7857 
other heart problems arthritis/rheumatism/fibrositis 44 0.5077 0.6006 0.5824 0.7798 0.7859 
 19 
other heart problems other problems of bones/joints/muscles 51 0.5182 0.5966 0.6098 0.7795 0.7925 
asthma arthritis/rheumatism/fibrositis 113 0.5300 0.6567 0.5819 0.8034 0.7854 
other respiratory complaints arthritis/rheumatism/fibrositis 33 0.5247 0.5841 0.5815 0.7811 0.7854 
arthritis/rheumatism/fibrositis back problems/slipped disc/spine/neck 346 0.5465 0.5827 0.6068 0.7849 0.8052 
arthritis/rheumatism/fibrositis other problems of bones/joints/muscles 227 0.5538 0.5821 0.6122 0.7856 0.7928 
arthritis/rheumatism/fibrositis unclassifiable  102 0.6068 0.5809 0.6150 0.7857 0.7772 
back problems/slipped disc/spine/neck other problems of bones/joints/muscles 37 0.5730 0.6053 0.6122 0.8049 0.7913 
 
 
 
